当前位置:产品中心>单抗/多抗

Anti-Human CD152/CTLA4 & PD-1 Bispecific Reference Antibody|抗人CD152/CTLA4和PD-1双特异性参考抗体(靶标:人CTLA-4/PD-1)

货号:RB9T37015543
  • 价格:面议
  • 点击数:399
  

产品介绍

产品参数

形态Liquid
宿主种属Humanized
克隆性Monoclonal
抗体亚型[V-kappa’-VH-h-CH2-CH3_V-kappa-VH’]2
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1mg/ml
内毒素水平Please contact the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4, Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
表达系统Mammalian Cells
登录号P16410 & Q15116
背景信息Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).<br>• Cancer immunotherapy using checkpoint blockade., PMID:29567705<br/>• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870<br/>• Immune-related adverse events of checkpoint inhibitors., PMID:32382051<br/>• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845<br/>• Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113<br/>• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885<br/>• Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160<br/>• Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858<br/>• Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360<br/>• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704<br/>
别名TetravalentBispecific, MGD019, MGD-019, MGD0192416595-46-3
备注For research use only. Not suitable for clinical or therapeutic use.